INTRODUCTION
Peroxisome-proliferator-activated receptor δ (PPARδ) nuclear receptor type 1, class 2 (NR1C2) is a member of the PPAR subfamily of nuclear receptors many of which have been shown to be critically involved in the control of cellular growth, differentiation and homeostasis (reviewed in [1] ). The PPAR subfamily comprises in addition to PPARδ also PPARα (NR1C1) and PPARγ (NR1C3). Numerous studies have clearly established roles for PPARα and PPARγ in the regulation of cellular growth, differentiation and lipid homeostasis [2] , whereas the biological significance of PPARδ has remained elusive. However, recent studies have identified the role of PPARδ in cholesterol metabolism [3] , adipocyte differentiation [4, 5] , neuronal function [6] , epidermal differentiation [7, 8] , colon cancer [9] and uterine implantation [10] .
Transactivation by PPARδ is mediated by RXR (retinoid X receptor)-PPARδ heterodimers bound to peroxisomeproliferator-response elements (PPREs) in the promoter region of target genes. The PPREs are generally of the direct repeat with 1-bp spacing (DR1) type, which is also the target of a number of related nuclear receptors. Relatively little is known about the molecular mechanisms controlling PPARδ-mediated transactivation. The transcriptional activity of nuclear receptors Abbreviations used : PPAR, peroxisome-proliferator-activated receptor ; RXR, retinoid X receptor ; RAR, retinoic acid receptor ; TR, thyroid hormone receptor ; HLBD, hinge and ligand-binding domain ; AF2, activator function 2 ; DBD, DNA-binding domain ; AD, activator domain ; RID, receptorinteracting domain ; DR1, direct repeat with 1 bp spacing ; ACO, acyl-CoA oxidase ; PPRE, peroxisome-proliferator response element ; GST, glutathione S-transferase ; NCoR, nuclear receptor corepressor ; SMRT, silencing mediator for retinoid and thyroid hormone receptor ; TBP, TATA-binding protein; cPGI 2 , cyclic prostaglandin I 2 ; T3, thyroid hormone ; ID-I/II, interaction domain I/II ; LBD, ligand-binding domain. 1 These authors have contributed equally to this work. 2 To whom correspondence should be addressed (e-mail kak!bmb.sdu.dk).
was found to interact equally well with interaction domains I and II of NCoR. In transient transfection experiments, NCoR and the related silencing mediator for retinoid and thyroid hormone receptor (SMRT) were shown to exert a marked dose-dependent repression of ligand-induced PPARδ-mediated transactivation ; in addition, transactivation induced by the cAMP-elevating agent forskolin was efficiently reduced to basal levels by NCoR as well as SMRT coexpression. Our results suggest that the transactivation potential of liganded PPARδ can be fine-tuned by interaction with NCoR and SMRT in a manner determined by the expression levels of corepressors and coactivators.
Key words : cAMP, SMRT, transcriptional repression.
depends on and is regulated by a complex interplay of coactivators and corepressors. Coactivator-dependent transactivation by nuclear receptors is facilitated when the nuclear receptor ligand-binding domain (LBD) adopts a conformation that allows the C-terminal helix of activator function 2 (AF2) to pack tightly against the body of the LBD, forming a surface that accommodates a short helical structure present in the receptor interaction domains of most coactivators [11] . The crystal structures of PPARδ and other nuclear receptors have revealed that this conformation of the LBD is the prevalent one upon ligand binding [12, 13] . A large number of coactivators have been identified and shown to interact with nuclear receptors in a ligand-dependent manner (reviewed in [14] ). In the unliganded state, several nuclear receptors have been found to interact with the nuclear receptor corepressors (NCoRs) [15] and silencing mediator for retinoid and thyroid hormone receptor (SMRT) [16] . These corepressors are evidently required for the active repressing function of unliganded thyroid hormone receptor (TR) and retinoic acid receptor (RAR) [17] and also of Rev-Erb [18] , chicken ovalbumin u0pstream promoter-transcription factor 1 (COUP-TF) [19] and DAX1 [20] . Moreover, NCoR and SMRT interact with antagonist-bound steroid receptors and appear essential for full antagonist activity [21] . Although the unliganded PPARα and PPARγ are not transcriptional repressors they have been shown to associate with NCoR and SMRT [22] [23] [24] .
Substructures of the LBD that are also involved in coactivator recruitment seem to play a role in the interactions of corepressors with nuclear receptors [25] [26] [27] [28] . The interaction domains of the corepressors contain extended helical structures, which are predicted to interact with the part of the LBD that has been shown to accommodate the short helical structure present in the coactivators [26, 27] . The ligand-induced folding of the AF2 helix probably precludes binding of these extended helical structures ; however, additional structures flanking the helices also appear to partake in the binding process, which may involve slightly different structures of different receptor LBDs [28] . NCoR also binds to RXR, but significant binding is only observed upon deletion of the RXR-AF2 helix [29] .
In the present study, we demonstrate physical and functional interaction between NCoR and PPARδ. Interestingly, we find that the ligand dependency of this interaction is conditional, as it is absent when assayed in itro, but prominent in i o. Moreover, both NCoR and SMRT repressed PPARδ-mediated transactivation, induced either by ligand or by a cAMP-elevating agent, suggest a high degree of flexibility in the regulation of the transcriptional potential of PPARδ.
EXPERIMENTAL Plasmids
Expression vectors for the yeast two-hybrid system pGBT9 (pG9), pGAD10 (pG10) and pGAD424 (pG4) were obtained from Clontech. pG9hNCoR (residues 1454 -2453) was generated by cloning the EcoRI fragment containing the partial cDNA of human NCoR (isolated in the yeast two-hybrid library screening) from pG10hNCoR (residues 1454 -2453), into the EcoRI site of pGBT9. pG10mNCoR (residues 1944 -2453) and pG10mNCoR (residues 1944 -2239) were constructed by cloning the BamHI NCoR fragments of pGEX-NCoR (residues 1944 -2453) and pGEX-NCoR (residues 1944 -2239) [30] respectively into the pGAD10 BamHI site. The EcoRI\XhoI mNCoR fragment from pGEX-NCoR (residues 2239-2453) [30] was cloned into the EcoRI-SalI sites of pGAD424 to generate the vector pG4mNCoR (residues 2239-2453). Full-length and truncated derivatives of mPPARδ cDNA were generated from pSG5-PPARδ [31] by PCR using BamHI-SalI-tagged primers and inserted into the BamHI-SalI sites of the two-hybrid vectors generating the vectors pG9mPPARδ (residues 1-440), pG9mPPARδ (residues 166 -440), pG9mPPARδ (residues 71-165) and pG9mPPARδ (residues 1-440). The hinge and ligandbinding domains (HLBD) of mPPARα (residues 166-468), mPPARγ (residues 203-505) and mPPARδ (residues 137-440) were cloned from the PPARα cDNA (GenBank2 accession no. X57638), the PPARγ cDNA (GenBank2 accession no. U09138) and pSG5-PPARδ into the BamHI-SalI sites of pGBT9 by PCR using BamHI-SalI-tagged primers, generating the vectors pG9mPPARα (residues 166 -468), pG9mPPARγ (residues 203-505) and pG9mPPARδ (residues 137-440).
For bacterial expression, the pGEX-NCoR expression vectors described above were used.
For protein expression in yeast a series of copper-inducible expression vectors (pCA) [32] were used. The mPPARδ cDNA was subcloned from pSG5-PPARδ into the pCA2 BamHI-SalI sites by PCR using BamHI-SalI-tagged primers. The rRXRα cDNA (GenBank2 accession no. L06482) was cloned into the pCA4 BamHI-SalI sites by PCR using BglII-SalI-tagged primers. For transient transfections, the reporter vectors pTK3xPPRE-luc [33] and pTK-4xUAS Gal -luc [16] , and expression vectors : pSG5-PPARα, pSG5-PPARδ, pSPORT-PPARγ2, pCMX-NCoR, pSV-β-galactosidase-control (Promega), pCMX-RXRα [34] , pBlueScriptKSj, pcG4-PPARα, pcG4-PPARδ and pcG4-PPARγ and pCMX-mSMRTα-fl (eSMRT) [35] were used. Yeast GAL4 (residues 1-147) was derived from pGBT9 by PCR to generate an optimized Kozak sequence and cloned into the SmaI site of pBlueScriptKSj. The GAL4 DNAbinding domain (DBD) (residues 1-147) was then excised and cloned into pcDNA1 generating pcG4. pcG4-PPARα, pcG4-PPARδ and pcG4-PPARγ were constructed by excising mPPARα cDNA (residues 164 -468), mPPARδ cDNA (residues 134-440) and mPPARγ cDNA (residues 200-505) from the pG9-PPARα (HLBD), pG9-PPARδ (HLBD) and pG9-PPARγ (HLBD), respectively (see above) and cloned into pcG4. NCoR (residues 2239-2453) was subcloned from pGEX-NCoR (residues 2239-2453) into pM (Clontech). All PCR-based constructions were verified by nucleotide sequencing.
Yeast two-hybrid library screening
A human leukaemia (Jurkat) MATCHMAKER library (Clontech) was screened with pG9-mPPARδ (HLBD) as bait in a mating-based two-hybrid screening as described by Bendixen and co-workers [36] .
Yeast two-hybrid assay
The yeast strain SFY526 (Clontech) was transformed with vectors expressing GAL4(DBD) fusion as bait and a GAL4(AD) (activator domain) fusion as the activator. Clones were selected on selection medium plates containing 2 % (w\v) glucose. Filter assays were performed according to the Clontech MATCH-MAKER manual. To quantify β-galactosidase activities, selected clones were grown in selection minimal medium with 2 % (w\v) glucose. At D '!! l 0.5, activators or vehicle were added. After 5 h the cultures were harvested, the cells were washed in Z-buffer [37] , resuspended in Z-buffer (j10 mM DTE) and cell density was measured spectrophotometrically. The β-galactosidase activity was measured either as described in [37] or by submitting the cells to one freeze-thaw cycle and lysing in 20 mM DTE, 0.055 % (w\v) SDS, 1 % (v\v) Triton X-100 in Z-buffer in microtitre plates. Subsequently, the β-galactosidase activity was measured in an automatic platereader (iEMS with automatic injection of o-nitro-phenyl-galactoside) using single kinetic mode. Each assay was performed twice on 4 -8 individual clones of each type. In addition, the ability of yeast transformants to grow in the presence of 3-amino-1,2,4-triazole, aminotriazol (Sigma), a competitive inhibitor of the HIS3 gene product, was used to detect functional interactions between PPARs and NCoR. For Western analysis of protein expression, anti-Gal4(DBD) (Clontech) and anti-TATA-binding protein (TBP) (Santa Cruz, sc-273) antibodies were used.
Dynabead DR1 pull out
High-salt yeast extracts were prepared as described previously [32] . A total of 40 µl of yeast extract was preincubated on ice for 15 min in a 176 µl reaction containing 60 mM KCl, 20 mM Tris\HCl, pH 7.5, 10% (v\v) glycerol, 2 mM DTE, 2 mM MgCl # , 80 µg\ml sonicated herring sperm DNA and protease inhibitors, with or without 10 µM cyclic prostaglandin I # (cPGI # ) or 1 µM BRL49653 as indicated. A biotinylated oligonucleotide containing the DR1 element of the rACO promoter [5h-biotin-C6-d(tcgactcccgaacgtgacctttgtcctggtcccctgtcgac)-3 annealed to complementary non-biotinylated oligonucleotide] was bound to streptavidin-coated paramagnetic beads (Dynabeads, M280, Dynal2) following the procedure recommended by Dynal2. After preincubation, the reaction was precleared for nonspecific Dynabead\DNA binding by incubation with Dynabeads (with non-DR1-oligo bound) for 10 min at room temperature. The beads for preclearing were then removed by magnetic force and 0.2 mg of probe beads was added to the reaction. Binding was allowed for 10 min at room temperature at 22 rpm end-over. Bacterially produced glutathione S-transferase (GST)-NCoR (residues 2239-2453) or GST, approx. 0.65 µg, was added to the reactions and binding was allowed for another 10 min at room temperature. The beads were pulled out by magnetic force, washed four times in 60 mM NaCl, 20 mM Tris\HCl, pH 7.5, 10 % (v\v) glycerol, 2 mM MgCl # , 2 mM DTE, protease inhibitors and bound proteins were eluted by boiling in 30 µl SDS\PAGE loading buffer. The proteins were resolved by electrophoresis, transferred to Immobilon P membrane and visualized by immunological detection using ECL2. The primary antibodies used were α-GST (Pharmacia), α-RXRα (D-20) (Santa Cruz Biotechnology), α-PPARδ and α-PPARγ2. The last two were kindly provided by Poul Grimaldi and Mitchell Lazar, respectively. Stripping was done by boiling in 20 mM Tris\HCl, pH 7.5, 0.2 % (w\v) SDS.
Peptide mapping
Bacterially produced GST-NCoR (residues 2239-2453) was subjected to SDS\PAGE on a 10 % (w\v) acrylamide gel. Bands were visualized with Coomassie-Blue staining, excised, in situ digested [38] and analysed by matrix-assisted laser-desorption\ ionization mass spectrometry (MALDI-MS) analysis. In order to determine precisely the truncation point (p1 residue), the GST-NCoR was also directly submitted to the same analysis.
In vitro transcription and translation
Full-length rPPARα, full-length mPPARδ, full-length mPPARγ, full-length rRXRα and full-length hTRβ1 cDNAs were transcribed and translated using the TnT reticulocyte lysate kit (Promega) in the presence of [$&S]methionine.
GST pull down
GST fusion proteins were expressed in Escherichia coli BL21(pGROESL) by induction with 0.1 mM isopropyl β--thiogalactoside at 30 mC. Proteins were isolated by cell lysis with a French press and purified according to the Pharmacia manual. In itro translated 10 µl of rPPARα, mPPARδ, mPPARγ and rRXRα were incubated in buffer A, [20 mM Tris\HCl, pH 8.5, 100 mM NaCl, 0.1 % (v\v) NP-40, 10 % (v\v) glycerol, protease inhibitors and 10 mg\ml BSA (essential fatty-acid free)] with 100 µM Wy14643, 25µM 2-bromopalmitate, 10 µM BRL49653, 10 µM cPGI # and 1 µM of thyroid hormone (T3) respectively for 15 min on ice. GST-NCoR coupled to glutathione beads was added and the interaction was allowed to proceed for 2 h at 4 mC. The beads were then washed three times in buffer A with ligand where appropriate and finally in 10 mM Tris\HCl, pH 8.5. The bound proteins were eluted by boiling in SDS\PAGE sample buffer and resolved by electrophoresis on a 10 % (w\v) SDS gel.
[$&S]Methionine-labelled proteins were visualized by autoradiography.
Transient transfections
NIH-3T3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco) containing 10 % (v\v) calf serum (Sigma). The cells were cultured in 21i5 cm# plates and transfected in triplicate at 50 % confluence, employing the DC-Chol lipofection procedure [39] in DMEM without calf serum. Cells were transfected with luciferase reporter vector, β-galactosidase expression vector for normalization, receptor expression vectors, NCoR expression vector and SMRT expression vector. pBlueScriptKSj was used to equalize the total quantity of transfected DNA. Six hours after transfection, the liposomes were removed and the medium was changed to DMEM containing 10 % (v\v) resin-charcoal-stripped calf serum and 1 µM BRL49653, 100 µM Wy14653 (TIC4), 25 µM 2-bromopalmitate, 5 µM cPGI # (Sigma), 0.5 µM L165041 (Merck Research Laboratories, NJ, U.S.A.), 10 µM forskolin or solvent (DMSO). Cells were harvested after 48 h and lysed in Galacto-Light (TROPIX) lysis buffer. Luciferase and β-galactosidase activity were measured in triplicate in microtitre plates in a Berthold MicroLumat LB96P luminometer. The luciferase values were normalized to β-galactosidase activity.
RESULTS

PPARδ interacts strongly with NCoR
A partial cDNA encoding the C-terminal 1000 amino acids (residues 1454 -2453) of the human NCoR was isolated in a yeast two-hybrid screening of a human leukaemia (Jurkat) cDNA library using the mouse PPARδ HLBD as bait. Further analysis using the yeast two-hybrid system showed that the isolated NCoR fragment interacted exclusively with the LBD (H1-H12 as defined by the crystal structure of the PPARδ LBD [12] ) of PPARδ ( Figure 1A) . Inclusion of further N-terminal domains of PPARδ appeared to neither enhance nor reduce the interaction with the NCoR fragment. In agreement with previous reports [22, 30] , we found that the NCoR fragment also interacted well with the PPARα and PPARγ HLBDs in the two-hybrid system. The relative interaction strength of the three PPAR subtypes with NCoR (residues 1454 -2453) was measured in a liquid culture yeast two-hybrid assay. As shown in Figure 1(B) , the strength of interaction was strongly PPAR subtype-dependent, with PPARδ exhibiting an almost 4-fold stronger interaction with NCoR than PPARα. Equal levels of expression of the three GAL4(DBD)-PPA(HLBD) fusion proteins were confirmed by Western blotting using immunodetection of yeast TBP for normalization of protein load ( Figure 1C ).
Ligand dependence of the PPARδ-NCoR interaction
The interaction of NCoR with nuclear receptors is generally characterized by a strong ligand dependency. Interactions between PPARα and NCoR, and between PPARγ and NCoR have previously been shown to exhibit some degree of ligand dependency in yeast and mammalian two-hybrid assay, respectively [22] [23] [24] . When cPGI # , which binds to all PPAR subtypes, was added to the liquid cultures in the yeast two-hybrid assay, the PPARα-NCoR (residues 1454 -2453) interaction was strongly reduced, whereas the PPARδ-NCoR and PPARγ-NCoR interactions were only modestly reduced (Figure 2A) . In a mammalian two-hybrid system, a pronounced ligand-dependent reduction of the interaction with NCoR was observed for all three PPAR subtypes ( Figure 2B ).
The NCoR receptor interaction domain (ID) is composed of two discrete nuclear receptor IDs [25] and one N-terminally located interaction-enhancing domain [25, 40] . Yeast two-hybrid analysis showed that PPARδ interacted in a ligand-dependent fashion with both the C-and N-terminal autonomous interaction domains (named ID-I and ID-II, respectively) ( Figure 2C ). Interaction between PPARδ and ID-II appeared weak. However, the strength of the interactions of the different NCoR fragments with PPARδ cannot be determined in this assay because the three fragments are expressed at very different levels as assessed by Western blotting (results not shown).
Using GST-NCoR fusions and in itro translated nuclear receptors for pull-down analyses, we found that TRβ as previously reported interacted strongly with the N-terminal NCoR ID-II fragment, whereas interaction with the C-terminal ID-I fragment was weak [25] . Interaction was significantly decreased by the addition of T3 ( Figure 2D ). On the other hand, PPARδ interacted equally well with the C-and N-terminal NCoR ID-I and ID-II fragments. Similar results were obtained with PPARα and PPARγ (results not shown). In the pull-down assays, PPARδ-NCoR interactions were unaffected by the addition of ligand ( Figures 2D and 3) . Addition of a 2-fold excess of in itro translated RXRα did not affect the NCoR-PPAR interactions in itro ( Figure 3 ). The same conclusion was reached using a yeast two-hybrid assay, where coexpression of RXR did not affect the interaction between NCoR and PPARδ (results not shown). Both PPAR and RXR were observed in the pull-down mixtures, although the RXR signals were very weak compared with the PPAR signals. Whether RXR was pulled down by direct interaction with NCoR or as part of a PPAR-RXR heterodimer, or whether NCoR binding to PPARδ impedes interaction between PPARδ and RXR cannot be concluded from this assay. Yet, as shown below, a preformed PPARδ-RXR heterodimer is able to recruit NCoR. In a control experiment (see Figure 3 ), the addition of T3 significantly reduced or completely abolished TRβ interaction with NCoR, confirming the functionality of the assay [15] . In agreement with previous reports, the TR signal was much stronger than the RXR signal in pull-down analyses [30] . Binding of nuclear receptors to cognate DNA response elements has been shown to enhance heterodimerization and influence the recruitment of cofactors [41, 42] . Thus the formation of a ternary complex consisting of RAR, RXR and an RAR response element enhanced recruitment of NCoR in the absence of ligands, but also enhanced ligand-dependent recruitment of the steroid receptor coactivator 1 [42] . It was reported that DNA binding of PPARγ prevented interaction with NCoR when assayed in electrophoretic mobility assays [30] . To investigate whether the PPARδ-NCoR interaction persisted in a DNAbound context and, if so, how ligands would affect this interaction, we tested the PPARδ-RXRα-NCoR complex formation on an oligonucleotide containing the ACO DR1. A biotinylated DNA probe containing the ACO DR1 was used to pull down RXRα and PPARδ from high-salt extracts of yeast expressing these receptors ( Figure 4A ). When bacterially produced GST-NCoR (residues 2239-2453) was added to the reaction it was pulled down with the DR1\RXRα- PPARδ complex. This implies the existence of an RXR-PPARNCoR complex bound to DR1. Interestingly, and in keeping with previously published functional assays [21] , we were also able to detect interaction between NCoR and a DR1\RXRα-PPARγ complex ( Figure 4B ). Small amounts of GST-NCoR were also pulled down using extracts of yeast expressing RXRα alone, consistent with previous reports showing weak interaction between RXRα and the NCoR ID-I [22] . Addition of 10 µM cPGI # did not diminish binding of NCoR to the DNA-bound PPARδ-RXRα heterodimer. Similarly, addition of 10 µM cPGI # or 1 µM BRL49653 did not decrease NCoR binding to the DNA-bound PPARγ-RXRα heterodimer (Figure 4 ). Other ligands including the RXR ligand 9-cis retinoic acid were tested with similar results (results not shown).
Figure 2 NCoR-PPAR interaction is ligand-dependent in vivo but not in vitro, and involves the entire NCoR RID
During purification from E. coli extracts, GST-NCoR was partially degraded. It appeared that RXRα predominantly pulled down the full-length fragment, whereas the PPAR-RXR complexes displayed no particular preference for the full-length fragment and even tended to pull down slightly more of a truncated form. To determine the degree of truncation, a sample of the GST-NCoR fusion protein was submitted to SDS\PAGE. Bands corresponding to the two largest peptide forms were excised and submitted to tryptic in-gel digestion followed by mass-spectrometric peptide mapping. The largest peptide was identified as full-length GST-NCoR (residues 2239-2453). The truncated peptide predominantly pulled down by PPARs was found to contain GST-NCoR (residues 2239-2377), thus lacking a part of the NCoR C-terminal which included the 38 amino-acid region previously shown to impair NCoR receptor-interacting domain (RID) interaction with TRβ [15] .
In conclusion, DNA binding of the PPARδ-RXRα heterodimer did not prevent interaction with NCoR (residues 2239-2453). PPARδ-NCoR interaction was ligand-dependent when assayed in a mammalian cell context, whereas addition of ligands did not affect interaction in the in itro assays. It is possible that additional factors present in i o or promoter context-dependent interactions are required for ligand-mediated release of NCoR from PPARδ, whereas the high-affinity binding of ligands to RAR and TR is sufficient to promote release of corepressors from these receptors also in itro.
NCoR is a potent repressor of PPARδ-mediated transactivation
To investigate the functional significance of the observed interactions between NCoR and PPARδ-RXR we expressed the receptors in NIH 3T3 cells and assayed the effect of coexpression of NCoR on the activity of a PPRE $ TK-Luc reporter construct ( Figure 5A ). NCoR coexpression led to a dose-dependent reduction of ligand-induced PPARδ-RXRα-mediated transactivation. Confirming previously published results [22] [23] [24] ,
Figure 3 NCoR-PPAR interaction is unaffected by the presence of RXRa
In vitro translated PPARα, PPARγ, PPARδ or TRβ were pulled down with GST-NCoR (residues 2239-2453) in the absence or presence of a 2-fold excess of in vitro translated RXRα and with or without addition of ligand (100 µM WY14643, 10 µM BRL49653, 25 µM 2-bromopalmitate or 1 µM T3).
Figure 4 NCoR is recruited to DNA-bound RXR-PPARδ and RXR-PPARγ complexes
A biotinylated DR1 containing DNA-oligo was bound to streptavidin-coupled magnetic beads and used to isolate RXRα and PPARδ (A) or PPARγ (B) from whole-cell extracts of yeast expressing these receptors. The reactions were performed in the absence or presence of either GST or GST-NCoR (residues 2239-2453) and with or without 10 µM cPGI 2 or BRL49653. Detection of isolated proteins was done by Western blotting.
NCoR coexpression also led to repression of the ligand-induced transcriptional activity of PPARα and PPARγ ( Figure 5A ), although repression of PPARα was significantly weaker than that observed for PPARγ and PPARδ. Using GAL4(DBD)-PPAR(HLBD) fusions and the GAL UAS Luc reporter, we observed significant, but less NCoR-mediated repression supporting the finding that NCoR interacted with LBDs of the PPARs. The PPARs are generally characterized as transcriptional activators without the repression potential of the related receptors TR, RAR and Rev-Erb. Accordingly, coexpression of NCoR did not repress the transcriptional activity of the reporter constructs below the basal levels of activity.
Our recent studies [4] supported by other work [43] have shown that cAMP-elevating agents enhance PPARδ-RXRmediated transactivation and cAMP-elevating agents and ligands synergistically induce PPARδ-mediated transactivation. Upon coexpression of NCoR, we observed a significant repression of PPARδ-mediated transactivation induced by the PPARδ-specific ligand, L165041, as well as transactivation induced by the cAMPelevating agent forskolin, alone or in synergy with L165041. Noticeably, NCoR is capable of total repression of the activity of the liganded PPARδ ( Figure 5C , left-hand panel). Most nuclear receptors appear to have a preference for interaction with either NCoR or the related corepressor, SMRT [21, 28, 30] , and repression of PPARγ-mediated transactivation through activation of the mitogen-activated protein kinase cascade was shown to be strongly dependent on SMRT, but not on NCoR [21] . Our results clearly demonstrate that NCoR potently represses PPARδ-mediated transactivation, and hence we decided to investigate whether PPARδ differed from PPARγ or whether PPARδ-mediated transactivation could be repressed by SMRT. Figure 5C (right-hand panel) demonstrates that coexpression of SMRT led to a dose-dependent repression of PPARδ-mediated transactivation similar to that obtained with NCoR coexpression ( Figure 5C ). Thus, PPARδ is a target for both NCoR and SMRT-mediated transcriptional repression.
DISCUSSION
Understanding the mechanisms determining ligand-dependent exchange of corepressors for coactivators is central to the understanding of nuclear receptor-dependent control of gene expression. In the work presented here, we demonstrate physical and functional interaction between NCoR and the three known PPAR subtypes. We show that the strength of NCoR interaction with the three PPAR subtypes followed the ranking order PPARδ PPARγ PPARα. The PPARs bind to the same type of DNA elements although with different affinities [44, 45] and, hence, competition for binding in conjunction with ligand availability, ligand-binding affinities and differences in the affinity for binding of corepressors and coactivators will ultimately determine the activity of genes harbouring PPRE elements in their promoters. We show that the corepressors NCoR and SMRT are capable of fully repressing PPARδ-mediated transactivation induced either by ligands or by cAMP-regulated signalling pathways. This suggests corepressors as general antagonists of the various stimuli inducing PPARδ-mediated transactivation.
Isolation of NCoR as a PPARδ-binding protein and the discovery that it represses ligand-induced, PPARδ-mediated transactivation raise the question as to how this repression takes place at the molecular level, taking into account that binding of ligand switches the structure of related nuclear receptors from an inactive\repressive form to an active form (reviewed in [14] ). With the elucidation of the crystal structures of the liganded and unliganded forms of the LBDs of PPARγ [13] and later of PPARδ [12] and PPARα [12, 46, 47] , it became clear that the PPARs deviate structurally from related nuclear receptors in several ways. The ligand-binding hydrophobic cavity of the PPAR LBDs is much larger and more spacious than those of other nuclear receptors, which explains the ability of the PPARs to accommodate a wide variety of structurally different classes of ligands. It also appeared that the PPAR ligands are oriented so that the polar headgroup of the ligand faces the AF2 helix and makes an intricate series of hydrogen bonds with amino-acid residues of the receptors including a conserved tyrosine residue in the C-terminal AF2 helix. This is in contrast with the structure determined for other liganded receptors, where the polar group(s) is facing away from the AF2 helix. Several studies have shown that different PPAR ligands mediate a differential pattern of interaction with cofactors [48] [49] [50] , suggesting that each ligand may stabilize the otherwise rather unstable LBD [51] in a particular conformation defined by the structure of the ligand. Direct evidence of a high degree of structural flexibility has been obtained by NMR spectroscopy of the PPARγ LBD [51] . This flexibility is consistent with a highly dynamic structure of the unliganded receptors as it was predicted based on the fact that the LBDs of the PPARs contain several additional helices and substructures compared with other crystallized receptors [12, 13, 47] . The notion of a very flexible PPAR structure was further supported by the discovery of a separate class of synthetic PPAR ligands which prevent both coactivator and corepressor interaction by freezing the PPARγ LBD in a conformation similar to that observed in the structure of the crystallized unliganded PPARγ LBD [24] . Thus corepressor as well as coactivator binding may require\prefer a conformation of the PPARs distinct from the ' canonical ' structure of the unliganded receptors. Further evidence in favour of the notion that corepressor binding induces a particular conformation of nuclear receptors was obtained in studies showing that corepressor binding imposed a structural alteration in the TR LBD. This alteration included a stabilized interaction between helix 1 and the remainder of the TR LBD, similar to that observed in ligand binding to the TR LBD [52] .
Assembly of the AF2 helix into the active AF2 structure appears necessary for stable coactivator recruitment, whereas it precludes corepressor interaction with the steroid receptors and strongly antagonizes corepressor interaction with the RARs and TRs [27] . Thus, it would appear that the flexibility of the AF2 helix is a determinant of the relative affinity of a receptor for corepressors and coactivators. We found that NCoR interacted strongly with PPARδ. This interaction was unaffected by the presence of ligands in itro, showing that ligand binding by itself did not preclude or significantly antagonize NCoR interaction. On the other hand, when tested in cell-based assays we observed a ligand-induced reduction of the PPARδ-NCoR interaction. Hence, in the cell-based assays the effect of ligands must be mediated by factors absent or present at insufficient levels in the in itro assays. Addition of ligand increases the affinity of PPARδ for coactivators, and it is therefore plausible that coactivator recruitment may be required for completion of the release of NCoR initiated by ligand binding. This idea is further supported by our observation that ligand-induced PPARδ-mediated transactivation in NIH 3T3 cells was repressed by corepressor coexpression in a dose-dependent manner, suggesting that corepressors when present at sufficiently high levels may exert a significant competition against ligand-induced coactivator binding to the PPARδ. Previously, it has been anticipated that the conformation of ligand-activatable nuclear receptors was mainly determined by the presence of ligands, which then dictated interactions with cofactors. We propose a model for PPARδ function where ligands may poise the PPARδ for receptormediated transactivation, whereas the actual magnitude of the transactivation depends on the equilibrium between binding of the actual coactivators and corepressors. This mechanism allows fine-tuning of PPARδ-mediated transactivation induced by various signalling pathways. 
